Combination of oncolytic herpes simplex Viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human Glioblastoma models

Neoplasia (United States)

Volumn 15, Issue 6, 2013, Pages 591-599

  Zhang, Wei ^a,b   Fulci, Giulia ^a   Wakimoto, Hiroaki ^a   Cheema, Tooba A ^a   Buhrman, Jason S ^a   Jeyaretna, Deva S ^c   Stemmer Rachamimov, Anat O ^a   Rabkin, Samuel D ^a   Martuza, Robert L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; CD31 ANTIGEN; INTERLEUKIN 12; ONCOLYTIC HERPES VIRUS; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84878664183     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13158     Document Type: Article

References (44)

1. Louis DN, Pomeroy SL, and Cairncross JG (2002). Focus on central nervous system neoplasia. Cancer Cell 1, 125-128.
2. Martuza RL, Malick A, Markert JM, Ruffner KL, and Coen DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
3. Fulci G and Chiocca EA (2003). Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front Biosci 8, e346-e360.
4. Aghi M, Rabkin S, and Martuza RL (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98, 38-50.
5. Liu TC, Castelo-Branco P, Rabkin SD, and Martuza RL (2008). Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 16, 1041-1047.
6. Post DE, Fulci G, Chiocca EA, and Van Meir EG (2004). Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 4, 41-51.
7. Kanai R, Wakimoto H, Cheema T, and Rabkin SD (2010). Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol 6, 619-634.
8. Kaur B, Cripe TP, and Chiocca EA (2009). "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 9, 341-355.
9. Friedman A, Tian JP, Fulci G, Chiocca EA, and Wang J (2006). Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 66, 2314-2319.
10. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103, 12873-12878.
11. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, et al. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 67, 9398-9406.
12. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99, 1768-1781.
13. Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weissleder R, et al. (2006). Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 14, 779-788.
14. Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, and Wick A (2013). Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 69, 95-101.
15. Piccioni D, Lai A, Nghiemphu P, and Cloughesy T (2012). Bevacizumab as first-line therapy for glioblastoma. Future Oncol 8, 929-938.
16. Tysome JR, Lemoine NR, and Wang Y (2009). Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes. Curr Opin Mol Ther 11, 664-669.
17. Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G, and Portella G (2008). Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 14, 6505-6514.
18. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, and Saeki Y (2008). Histone deacetylase inhibitors augment antitumor efficacy of herpesbased oncolytic viruses. Mol Ther 16, 1546-1555.
19. Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, and Martuza RL (2011). Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther 20, 37-45.
20. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, and Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
21. Dell'Eva R, Pfeffer U, Indraccolo S, Albini A, and Noonan D (2002). Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy. Endothelium 9, 3-10.
22. Perri SR, Annabi B, and Galipeau J (2007). Angiostatin inhibits monocyte/ macrophage migration via disruption of actin cytoskeleton. FASEB J 21, 3928-3936.
23. Stack MS, Gately S, Bafetti LM, Enghild JJ, and Soff GA (1999). Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrixenhanced plasminogen activation. Biochem J 340(pt 1), 77-84.
24. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, and Black PM (1998). Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58, 4654-4659.
25. Wahl ML, Moser TL, and Pizzo SV (2004). Angiostatin and anti-angiogenic therapy in human disease. Recent Prog Horm Res 59, 73-104.
26. Ma HI, Lin SZ, Chiang YH, Li J, Chen SL, Tsao YP, and Xiao X (2002). Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther 9, 2-11.
27. Wong RJ, Chan MK, Yu Z, Ghossein RA, Ngai I, Adusumilli PS, Stiles BM, Shah JP, Singh B, and Fong Y (2004). Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10, 4509-4516.
28. Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, Mancino A, Sica A, and Noonan DM (2009). Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med 7, 5.
29. Gyorffy S, Palmer K, Podor TJ, Hitt M, and Gauldie J (2001). Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol 166, 6212-6217.
30. Todo T, Martuza RL, Rabkin SD, and Johnson PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98, 6396-6401.
31. Todo, T (2009). A clinical study of a replication-competent, recombinant herpes simplex virus type 1 (G47delta) in patients with progressive glioblastoma. http://appswhoint/trialsearch/trialaspx?trialid=JPRN-UMIN000002661; Japan Primary Registries Network (Internet), Wako-shi (Saitama), National Institute of Public Health (Japan). 2008 Oct 16. Identifier JPRN-UMIN000002661.
32. Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69, 3472-3481.
33. Wakimoto H, Mohapatra G, Kanai R, Curry WT Jr, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, et al. (2011). Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol 14, 132-144.
34. Pandita A, Aldape KD, Zadeh G, Guha A, and James CD (2004). Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39, 29-36.
35. Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ, St-Louis M, Shah JP, Johnson PA, and Fong Y (2001). Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12, 253-265.
36. Kuroda T, Martuza RL, Todo T, and Rabkin SD (2006). Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 6, 40.
37. Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, and Gillespie GY (2005). Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 7, 213-224.
38. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, and Markert JM (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 97, 2208-2213.
39. Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, and Markert JM (2005). Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 12, 359-368.
40. Parker JN, Pfister LA, Quenelle D, Gillespie GY, Markert JM, Kern ER, and Whitley RJ (2006). Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine 24, 1644-1652.
41. Toda M, Martuza RL, Kojima H, and Rabkin SD (1998). In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160, 4457-4464.
42. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, and Martuza RL (2006). Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 13, 253-265.
43. Varghese S, Rabkin SD, Nielsen PG, Wang W, and Martuza RL (2006). Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 12, 2919-2927.
44. Ino Y, Saeki Y, Fukuhara H, and Todo T (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin- 18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12, 643-652.